NO322090B1 - Topisk farmasoytisk formulering inneholdende dimeticon, samt fremstilling derav - Google Patents
Topisk farmasoytisk formulering inneholdende dimeticon, samt fremstilling derav Download PDFInfo
- Publication number
- NO322090B1 NO322090B1 NO20013103A NO20013103A NO322090B1 NO 322090 B1 NO322090 B1 NO 322090B1 NO 20013103 A NO20013103 A NO 20013103A NO 20013103 A NO20013103 A NO 20013103A NO 322090 B1 NO322090 B1 NO 322090B1
- Authority
- NO
- Norway
- Prior art keywords
- topical pharmaceutical
- water
- pharmaceutical formulation
- dimethicone
- formulation according
- Prior art date
Links
- 239000004205 dimethyl polysiloxane Substances 0.000 title claims description 54
- 235000013870 dimethyl polysiloxane Nutrition 0.000 title claims description 54
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 title claims description 54
- 229940008099 dimethicone Drugs 0.000 title claims description 53
- 230000000699 topical effect Effects 0.000 title claims description 45
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 42
- 238000002360 preparation method Methods 0.000 title claims description 5
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 68
- 239000000203 mixture Substances 0.000 claims description 64
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims description 56
- 238000009472 formulation Methods 0.000 claims description 54
- 229960004150 aciclovir Drugs 0.000 claims description 47
- 150000005846 sugar alcohols Polymers 0.000 claims description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 34
- 239000003921 oil Substances 0.000 claims description 28
- 229960004063 propylene glycol Drugs 0.000 claims description 23
- 239000012071 phase Substances 0.000 claims description 20
- 239000000839 emulsion Substances 0.000 claims description 19
- 239000006071 cream Substances 0.000 claims description 18
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 16
- 239000003995 emulsifying agent Substances 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 13
- 239000008346 aqueous phase Substances 0.000 claims description 12
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims description 11
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 claims description 11
- 239000008213 purified water Substances 0.000 claims description 11
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 9
- 239000004358 Butane-1, 3-diol Substances 0.000 claims description 8
- 235000019437 butane-1,3-diol Nutrition 0.000 claims description 8
- -1 polyoxyethylene Polymers 0.000 claims description 8
- 239000003381 stabilizer Substances 0.000 claims description 7
- 239000000725 suspension Substances 0.000 claims description 7
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 6
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 6
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 6
- 239000002480 mineral oil Substances 0.000 claims description 5
- 239000003883 ointment base Substances 0.000 claims description 5
- 235000010446 mineral oil Nutrition 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 3
- 150000005215 alkyl ethers Chemical class 0.000 claims description 3
- 229940082500 cetostearyl alcohol Drugs 0.000 claims description 3
- 229960000541 cetyl alcohol Drugs 0.000 claims description 3
- 238000004945 emulsification Methods 0.000 claims description 3
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 3
- 229920001992 poloxamer 407 Polymers 0.000 claims description 3
- 229940044476 poloxamer 407 Drugs 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 2
- 239000011259 mixed solution Substances 0.000 claims description 2
- 239000012188 paraffin wax Substances 0.000 claims description 2
- 235000019271 petrolatum Nutrition 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 230000001050 lubricating effect Effects 0.000 claims 2
- 229940082337 dimethicone 20 Drugs 0.000 claims 1
- 239000003871 white petrolatum Substances 0.000 claims 1
- 206010015150 Erythema Diseases 0.000 description 24
- 231100000321 erythema Toxicity 0.000 description 24
- 238000011282 treatment Methods 0.000 description 18
- 208000015181 infectious disease Diseases 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- 229940107931 zovirax Drugs 0.000 description 8
- 230000000840 anti-viral effect Effects 0.000 description 7
- 206010037888 Rash pustular Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 208000029561 pustule Diseases 0.000 description 6
- 239000003925 fat Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 230000009385 viral infection Effects 0.000 description 5
- 208000007514 Herpes zoster Diseases 0.000 description 4
- 208000036142 Viral infection Diseases 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000012049 topical pharmaceutical composition Substances 0.000 description 4
- 241000700198 Cavia Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000004898 Herpes Labialis Diseases 0.000 description 3
- 206010022998 Irritability Diseases 0.000 description 3
- 206010067152 Oral herpes Diseases 0.000 description 3
- 206010033733 Papule Diseases 0.000 description 3
- 241000700584 Simplexvirus Species 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000008387 emulsifying waxe Substances 0.000 description 3
- 238000011554 guinea pig model Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- ILCOCZBHMDEIAI-UHFFFAOYSA-N 2-(2-octadecoxyethoxy)ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCO ILCOCZBHMDEIAI-UHFFFAOYSA-N 0.000 description 2
- 201000006082 Chickenpox Diseases 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000001688 Herpes Genitalis Diseases 0.000 description 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 2
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 206010046980 Varicella Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 201000004946 genital herpes Diseases 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- OBETXYAYXDNJHR-SSDOTTSWSA-M (2r)-2-ethylhexanoate Chemical compound CCCC[C@@H](CC)C([O-])=O OBETXYAYXDNJHR-SSDOTTSWSA-M 0.000 description 1
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
- UGBLISDIHDMHJX-UHFFFAOYSA-N 1-(4-fluorophenyl)-4-[4-(2-methoxyphenyl)piperazin-1-yl]butan-1-one;hydrochloride Chemical compound [Cl-].COC1=CC=CC=C1N1CC[NH+](CCCC(=O)C=2C=CC(F)=CC=2)CC1 UGBLISDIHDMHJX-UHFFFAOYSA-N 0.000 description 1
- HBXWUCXDUUJDRB-UHFFFAOYSA-N 1-octadecoxyoctadecane Chemical class CCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCC HBXWUCXDUUJDRB-UHFFFAOYSA-N 0.000 description 1
- LGEZTMRIZWCDLW-UHFFFAOYSA-N 14-methylpentadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C LGEZTMRIZWCDLW-UHFFFAOYSA-N 0.000 description 1
- SFAAOBGYWOUHLU-UHFFFAOYSA-N 2-ethylhexyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(CC)CCCC SFAAOBGYWOUHLU-UHFFFAOYSA-N 0.000 description 1
- ICIDSZQHPUZUHC-UHFFFAOYSA-N 2-octadecoxyethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCO ICIDSZQHPUZUHC-UHFFFAOYSA-N 0.000 description 1
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 208000000903 Herpes simplex encephalitis Diseases 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229920002675 Polyoxyl Polymers 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000008278 cosmetic cream Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940031578 diisopropyl adipate Drugs 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000008309 hydrophilic cream Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 229940078545 isocetyl stearate Drugs 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 229940059904 light mineral oil Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000008251 pharmaceutical emulsion Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229940098760 steareth-2 Drugs 0.000 description 1
- 229940100458 steareth-21 Drugs 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9828620.6A GB9828620D0 (en) | 1998-12-23 | 1998-12-23 | Medicaments |
| PCT/EP1999/010155 WO2000038695A2 (en) | 1998-12-23 | 1999-12-21 | Aciclovir compositions containing dimethicone |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20013103D0 NO20013103D0 (no) | 2001-06-21 |
| NO20013103L NO20013103L (no) | 2001-08-20 |
| NO322090B1 true NO322090B1 (no) | 2006-08-14 |
Family
ID=10845017
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20013103A NO322090B1 (no) | 1998-12-23 | 2001-06-21 | Topisk farmasoytisk formulering inneholdende dimeticon, samt fremstilling derav |
Country Status (27)
| Country | Link |
|---|---|
| EP (1) | EP1140117B1 (zh) |
| JP (1) | JP4145493B2 (zh) |
| KR (1) | KR100707329B1 (zh) |
| CN (2) | CN100415237C (zh) |
| AR (1) | AR021993A1 (zh) |
| AT (1) | ATE236644T1 (zh) |
| AU (1) | AU768989B2 (zh) |
| BR (1) | BR9916524A (zh) |
| CA (1) | CA2356895A1 (zh) |
| CZ (1) | CZ295770B6 (zh) |
| DE (2) | DE69906796T2 (zh) |
| DK (1) | DK1140117T3 (zh) |
| ES (1) | ES2196910T3 (zh) |
| GB (2) | GB9828620D0 (zh) |
| HK (2) | HK1039275A1 (zh) |
| HU (1) | HU230542B1 (zh) |
| IL (2) | IL143833A0 (zh) |
| NO (1) | NO322090B1 (zh) |
| NZ (1) | NZ512457A (zh) |
| PE (1) | PE20001351A1 (zh) |
| PL (1) | PL196629B1 (zh) |
| PT (1) | PT1140117E (zh) |
| SI (1) | SI1140117T1 (zh) |
| TR (1) | TR200102482T2 (zh) |
| TW (1) | TW585768B (zh) |
| WO (1) | WO2000038695A2 (zh) |
| ZA (1) | ZA200105071B (zh) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2005824A1 (de) † | 2007-06-21 | 2008-12-24 | Bayer CropScience AG | Wirkstoffsuspensionen in Glycerin |
| WO2010046861A1 (en) * | 2008-10-21 | 2010-04-29 | Novodermix International Limited | Composition for treatment of epithelial tissue |
| WO2012107575A1 (en) * | 2011-02-10 | 2012-08-16 | Moberg Derma Ab | Novel formulations for dermal, transdermal and mucosal use 2 |
| WO2015082172A1 (en) * | 2013-12-03 | 2015-06-11 | Zzip Ag | Polydimethylsiloxane for the treatment of viral infections |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2080106B (en) * | 1980-07-18 | 1984-03-07 | Weelcome Foundation Ltd | Acyclovin preparations |
| AU5381590A (en) * | 1989-04-24 | 1990-10-25 | Syntex (U.S.A.) Inc. | Topical antiviral pharmaceutical composition containing a nonionic surfactant |
| GB9114939D0 (en) * | 1991-07-11 | 1991-08-28 | Smithkline Beecham Plc | Pharmaceutical formulation |
| FR2728167A1 (fr) * | 1994-12-15 | 1996-06-21 | Cird Galderma | Composition cosmetique ou dermatologique sous forme d'une emulsion eau dans huile a teneur elevee en hydroxyacides |
| FR2737118B1 (fr) * | 1995-07-28 | 1997-09-05 | Oreal | Composition dermatologique ou pharmaceutique, procede de preparation et utilisation |
-
1998
- 1998-12-23 GB GBGB9828620.6A patent/GB9828620D0/en not_active Ceased
-
1999
- 1999-12-21 DE DE69906796T patent/DE69906796T2/de not_active Expired - Lifetime
- 1999-12-21 GB GB0117795A patent/GB2362105B/en not_active Expired - Lifetime
- 1999-12-21 BR BR9916524-4A patent/BR9916524A/pt not_active Application Discontinuation
- 1999-12-21 DE DE29924428U patent/DE29924428U1/de not_active Expired - Lifetime
- 1999-12-21 KR KR1020017008079A patent/KR100707329B1/ko not_active IP Right Cessation
- 1999-12-21 WO PCT/EP1999/010155 patent/WO2000038695A2/en not_active Application Discontinuation
- 1999-12-21 NZ NZ512457A patent/NZ512457A/en not_active IP Right Cessation
- 1999-12-21 PL PL349505A patent/PL196629B1/pl unknown
- 1999-12-21 IL IL14383399A patent/IL143833A0/xx active IP Right Grant
- 1999-12-21 CZ CZ20012332A patent/CZ295770B6/cs not_active IP Right Cessation
- 1999-12-21 TR TR2001/02482T patent/TR200102482T2/xx unknown
- 1999-12-21 AT AT99965505T patent/ATE236644T1/de active
- 1999-12-21 PT PT99965505T patent/PT1140117E/pt unknown
- 1999-12-21 AU AU20997/00A patent/AU768989B2/en not_active Expired
- 1999-12-21 CA CA002356895A patent/CA2356895A1/en not_active Abandoned
- 1999-12-21 CN CNB2004100420150A patent/CN100415237C/zh not_active Expired - Fee Related
- 1999-12-21 EP EP99965505A patent/EP1140117B1/en not_active Expired - Lifetime
- 1999-12-21 PE PE1999001302A patent/PE20001351A1/es not_active Application Discontinuation
- 1999-12-21 JP JP2000590647A patent/JP4145493B2/ja not_active Expired - Fee Related
- 1999-12-21 HU HU0104594A patent/HU230542B1/hu not_active IP Right Cessation
- 1999-12-21 SI SI9930324T patent/SI1140117T1/xx unknown
- 1999-12-21 CN CNB99816156XA patent/CN1191834C/zh not_active Expired - Fee Related
- 1999-12-21 DK DK99965505T patent/DK1140117T3/da active
- 1999-12-21 ES ES99965505T patent/ES2196910T3/es not_active Expired - Lifetime
- 1999-12-22 AR ARP990106684A patent/AR021993A1/es not_active Application Discontinuation
-
2000
- 2000-01-07 TW TW089100208A patent/TW585768B/zh not_active IP Right Cessation
-
2001
- 2001-06-19 IL IL143833A patent/IL143833A/en not_active IP Right Cessation
- 2001-06-20 ZA ZA200105071A patent/ZA200105071B/en unknown
- 2001-06-21 NO NO20013103A patent/NO322090B1/no not_active IP Right Cessation
-
2002
- 2002-01-08 HK HK02100122.9A patent/HK1039275A1/zh unknown
-
2005
- 2005-01-03 HK HK05100005.8A patent/HK1067548A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CZ285275B6 (cs) | Topická farmaceutická kompozice | |
| PL186354B1 (pl) | Jałowe kompozycje farmaceutyczne oraz sposoby ograniczania potencjału wzrostowego drobnoustrojów i poprawiania czasu stosowania emulsji | |
| EP0044543B1 (en) | Topical formulations of 9-(2-hydroxyethoxymethyl) guanine | |
| CA2782441A1 (en) | Topical use of hydroxytyrosol and derivatives for the prevention of hiv infection | |
| US20170020882A1 (en) | Antiviral formulation | |
| WO1997034607A1 (en) | Topical formulations of aciclovir | |
| NO322090B1 (no) | Topisk farmasoytisk formulering inneholdende dimeticon, samt fremstilling derav | |
| WO1999012545A2 (en) | Medicaments containing acyclovir | |
| CN106109412A (zh) | 氟比洛芬酯脂微球注射液及其制备方法 | |
| JP2545317B2 (ja) | 医薬製剤 | |
| KR100608963B1 (ko) | 프로필렌 글리콜 및 이소프로필 알칸산 에스테르를포함하는 항바이러스 제제 | |
| WO1997045123A1 (en) | Topical pharmaceutical formulations comprising aciclovir | |
| MXPA01006490A (en) | Aciclovir compositions containing dimethicone | |
| RU2175230C1 (ru) | Фармацевтическая композиция с противовирусной активностью и способ ее получения | |
| WO2019002367A1 (en) | TOPICAL COMPOSITIONS FOR THE TREATMENT OF DERMATOLOGICAL DISEASES | |
| JP6347858B2 (ja) | 不妊症治療用経腟ホスホジエステラーゼ阻害剤含有医薬組成物 | |
| Ed-Drourh | Justification of the composition of a soft medicinal product for the treatment of herpes infection | |
| KR100358243B1 (ko) | 프로포폴및에데테이트를함유하는수중유에멀션 | |
| JPH09143096A (ja) | ウィルス疾患用医薬組成物 | |
| KR19990046153A (ko) | 프로포폴및에데테이트를함유하는수중유에멀션 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: GLAXO GROUP LTD, GB |
|
| MM1K | Lapsed by not paying the annual fees |